VRCA, US92511W2070

Verrica reports USD 5.86 million revenue. Target for Verrica Pharmaceuticals stock is USD 12.67

Published on 10/20/2026 at 13:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Verrica Pharmaceuticals stock costs EUR 3.08 on October 20, 2026. Second-quarter GAAP net loss was USD 13.15 million and cash was USD 11.20 million.

Financing and operating metrics

Verrica announced financing of up to USD 27.50 million on October 14, 2026.
Second-quarter 2026 revenue reached USD 5.86 million, while GAAP net loss was USD 13.15 million.
Verrica Pharmaceuticals stock traded at EUR 3.08 at 1:34 p.m. CEST at Lang & Schwarz on October 20, 2026.
MarketBeat reported a five-firm consensus Hold rating and an average USD 12.67 target on October 9, 2026.

VRCA, US92511W2070, Illustration mit AI erstellt.

Verrica Pharmaceuticals (US92511W2070) was trading at EUR 3.08 at Lang & Schwarz on October 20, 2026 at 1:34 p.m. CEST. The company reported second-quarter revenue of USD 5.86 million and announced financing of up to USD 27.50 million, according to Benzinga on October 14, 2026.

Revenue growth meets financing support

Verrica's second-quarter 2026 revenue consisted of USD 5.10 million in U.S. YCANTH net product revenue and USD 0.80 million in license and collaboration revenue. Revenue rose from USD 5.02 million in the first quarter of 2026, while GAAP net loss widened from USD 9.68 million to USD 13.15 million, according to Benzinga.

Cash stood at USD 11.20 million on June 30, 2026. The new facility can provide up to USD 27.50 million, with USD 12.50 million immediately available and another USD 15.00 million tied to revenue and operational milestones.

Three milestones frame the pipeline

In May 2026, Verrica presented Phase 2 VP315 data showing a 67 percent reduction in the size of 14 untreated non-target basal cell lesions among nine subjects, according to Benzinga. In June 2026, the company and partner Torii Pharmaceutical dosed the first patients in the second pivotal Phase 3 common-warts trial; Verrica said Torii is funding the first USD 40.00 million, or about 90 percent, of that program's current budget.

On October 14, 2026, management said the financing could extend its cash runway into 2028. The same update said Verrica would receive 60 percent of net selling price from its Israel distribution agreement, plus up to USD 8.20 million in regulatory and commercial milestones.

What does the funding change?

The financing reduces near-term pressure on a business that is increasing commercial and research spending. Second-quarter research and development expenses reached USD 6.00 million, while selling, general and administrative expenses were USD 10.30 million, excluding stock-based compensation, according to Benzinga. For market context, MarketBeat reported on October 9, 2026 that five firms had a consensus Hold rating and an average 12-month target of USD 12.67.

Clinical dates set the next markers

Fidelity reported that Verrica presented YCANTH data at the PeDRA Annual Conference from October 15 through October 17, 2026. Management expects top-line data from the common-warts program in mid-2027, subject to enrollment progress.

Stock price and company scale

Verrica develops dermatology treatments, including YCANTH for molluscum contagiosum and VP315 for skin cancer. MarketBeat listed a USD 71.8 million market capitalization and a USD 3.28 to USD 9.82 52-week range on October 9, 2026.

Verrica Pharmaceuticals was trading at EUR 3.08 at Lang & Schwarz on October 20, 2026 at 1:34 p.m. CEST.